SCHEMBL21484628

SCHEMBL21484628

COc1cccc(-c2csc(N)n2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
NPC1 O15118 6/20 0.51
MAPT P10636 6/20 0.51
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
POLB P06746 1/20 0.51
FBP1 P09467 1/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
BTK Q06187 1/20 0.46
HSD17B10 Q99714 4/20 0.45
LTA4H P09960 3/20 0.45
KDM4E B2RXH2 3/20 0.44
CYP3A4 P08684 2/20 0.43
GFER P55789 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3155981 0.81 BTK (0.61) ALDH1A1BTKKDM4EHPGD
SCHEMBL31387201 0.77 CCR1 (0.61) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL2483921 0.77 CCR1 (0.61) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL22290651 0.77 MAPT (0.54) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL25393863 0.74 APP (0.41) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL25393860 0.74 APP (0.41) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL15624596 0.73 BTK (0.41) ALDH1A1NPC1RAB9ABTK
SCHEMBL13745852 0.73 BTK (0.41) BTK
SCHEMBL12592141 0.73 FBP1 (0.51) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4134738 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 ALDH1A1 1635/4885NPC1 3280/4885MAPT 1351/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 ALDH1A1 1635/4885NPC1 3280/4885MAPT 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.